Olfactory Deficits in MCI as Predictor of Improved Cognition on Donepezil

PHASE4CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Mild Cognitive Impairment
Interventions
DRUG

Donepezil

Donepezil 5mg will be given for 4 weeks and if tolerated, the dose will be increased to 10 mg per day. The dose range of 5 to 10 mg of donepezil per day will be continued for the study duration, and this is the recommended dose for donepezil in the treatment of mild to moderate Alzheimer's disease.

DRUG

Atropine

A single acute dose of 1 mg of atropine nasal spray is administered to the nostril. The dose chosen reflects clinical doses typically used by Ear, Nose, and Throat (ENT) physicians.

Trial Locations (1)

10032

New York State Psychiatric Institute, New York

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

New York State Psychiatric Institute

OTHER

NCT01845636 - Olfactory Deficits in MCI as Predictor of Improved Cognition on Donepezil | Biotech Hunter | Biotech Hunter